富祥藥業(300497.SZ):永太科技擬清倉減持不超583.561萬股
格隆匯12月3日丨富祥藥業(300497.SZ)公佈,公司於2021年12月3日收到股東永太科技(002326.SZ)出具的《關於擬減持我司持有的江西富祥藥業股份有限公司股票的通知》,永太科技擬自該公吿發布之日起3個交易日後的6個月內,以集中競價、大宗交易方式根據證券市場情況擇機出售不超過583.561萬股公司股票。
截止該公吿日,永太科技持有公司股份583.561萬股,佔目前剔除公司回購專用賬户中的股份後的總股本的1.07%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.